The Dynamism of IV Safety

March 2020 : IV Safety - Vol. 17 No. 3 - Page #1

Intravenous medication therapy is at the crux of clinical pharmacy practice, and its risks are well known. Given the ever-increasing complexity of a wide range of IV-administered compounds, the term IV Safety can take on multiple meanings. The first consideration is the safety and sterility of the IV product itself. But careful consideration must be given to safe handling of IV medications, particularly antineoplastic agents, and this mandate extends well beyond the walls of the pharmacy or cleanroom; we must embrace that cradle-to-grave life cycle so commonly referred to.

Hence, we further our ongoing commitment to covering important topics throughout the entire IV safe-handling gamut. In this month’s supplement, we provide tips on ensuring IV safety. In addition, sterile compounding experts discuss a few different perspectives on the use and proper utilization of closed system drug-transfer devices.

As we continue to await the final implementation of USP General Chapter <800>, as well as the revisions to Chapter <797>, it is vital that safe handling initiatives remain top of mind. As these are topics regularly covered in Pharmacy Purchasing & Products, we encourage you to visit to claim or renew your free account access, and take a little time to review our recent coverage of IV safety and other important issues. It will be time well spent.

Ensuring IV safety for both patients and practitioners is as essential a role as the pharmacy director has; we applaud those who take it as seriously as it requires. For those on the road to compliance with internal and external regulations, we hope you will continue to turn to PP&P for the answers and guidance you need.

All the best,

R. Mitchell Halvorsen


Like what you've read? Please log in or create a free account to enjoy more of what has to offer.

Current Issue

Enter our Sweepstakes now for your chance to win the following prizes:

Just answer the following quick question for your chance to win:

To continue, you must either login or register: